Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway.
Neurochemistry International September 2018 Mauren K Tavares, Suellen Dos Reis, Nicolle Platt et al.
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most robust neurobiological findings in the pathophysiology of major depressive disorder (MDD) over the last 40 years. The persistent increase in glucocorticoids levels induces morphological and anatomical changes in the brain, especially in the hippocampus. Ketamine represents a major advance for the treatment of MDD,...
DOI: 10.1016/j.neuint.2018.05.006 (opens in new tab)
Full text (opens in new tab)
Ketamine
Agmatine
Akt
Ht22
+3